Lucatumumab

立即咨询

Lucatumumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

903512-50-5

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

HCD122

产品介绍

Lucatumumab (HCD122) 是一种全人抗CD40拮抗剂单克隆抗体，可阻断CD40/ CD40L 介导的信号通路。Lucatumumab 可有效介导抗体依赖性细胞介导的细胞毒性 (ADCC) 和肿瘤细胞清除，可用于顽固性淋巴瘤、慢性淋巴细胞白血病 (CLL) 和多发性骨髓瘤研究。

生物活性

Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research^[1]^[2].

IC₅₀& Target

CD40

体外研究
(In Vitro)

Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%^[1].
Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells^[1].
Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells^[1].

Cell Viability Assay^[1]

Cell Line:	B-cell chronic lymphocytic leukemia (B-CLL)
Concentration:	0.001 to 10 μg/mL
Incubation Time:	72 hours; 37 ℃
Result:	Inhibited B-CLL growth with an ED₅₀of 14 pM and a average maximal lysis of B-CLL cells of 49%.

Clinical Trial

性状

Liquid

CAS 号

903512-50-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.